LMF Acquisition Opportunities called an Oct. 18 meeting for shareholders to vote on the proposed merger with SeaStar Medical, a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. The SPAC’s registration statement has been declared effective by the SEC.
Announced in April, the deal has a combined enterprise value of $85 million.
The SPAC, which in abbreviated form is known as LMFAO, raised $90 million in a January 2021 IPO with plans at that time to focus on acquiring a business within the financial services industry and related sectors, including FinTech. The company was focusing on acquisitions with an enterprise value of approximately $250 million to $500 million.
The Dow Chemical Company Pension Plans, as existing investors of SeaStar Medical, are participating in a PIPE supporting the deal. Read more.
